Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 96 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2014', provides an overview of the Anaplastic Large Cell Lymphoma (ALCL)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anaplastic Large Cell Lymphoma (ALCL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Large Cell Lymphoma (ALCL) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anaplastic Large Cell Lymphoma (ALCL)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Anaplastic Large Cell Lymphoma (ALCL) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Anaplastic Large Cell Lymphoma (ALCL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Anaplastic Large Cell Lymphoma (ALCL) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Anaplastic Large Cell Lymphoma (ALCL)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Anaplastic Large Cell Lymphoma (ALCL) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Anaplastic Large Cell Lymphoma (ALCL) Overview 8
Therapeutics Development 9
Pipeline Products for Anaplastic Large Cell Lymphoma (ALCL) - Overview 9
Pipeline Products for Anaplastic Large Cell Lymphoma (ALCL) - Comparative Analysis 10
Anaplastic Large Cell Lymphoma (ALCL) - Therapeutics under Development by Companies 11
Anaplastic Large Cell Lymphoma (ALCL) - Therapeutics under Investigation by Universities/Institutes 12
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Anaplastic Large Cell Lymphoma (ALCL) - Products under Development by Companies 16
Anaplastic Large Cell Lymphoma (ALCL) - Products under Investigation by Universities/Institutes 17
Anaplastic Large Cell Lymphoma (ALCL) - Companies Involved in Therapeutics Development 18
Akron Molecules AG 18
AstraZeneca PLC 19
Bayer AG 20
Celon Pharma Sp. z o.o. 21
Novartis AG 22
Pfizer Inc. 23
Sareum Holdings plc 24
Seattle Genetics, Inc. 25
Sigma-Tau S.p.A. 26
Teva Pharmaceutical Industries Limited 27
Anaplastic Large Cell Lymphoma (ALCL) - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
AKR-303 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
AZD-3463 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
brentuximab vedotin - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
CEP-28122 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
CEP-37440 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
copanlisib - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
crizotinib - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Drug to Inhibit ALK for Anaplastic Large Cell Lymphoma - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
KRA-0008 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
luminespib - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
pegaspargase - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
SH-7129 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Small Molecules to Inhibit Aurora and ALK Kinase for Oncology - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Anaplastic Large Cell Lymphoma (ALCL) - Recent Pipeline Updates 62
Anaplastic Large Cell Lymphoma (ALCL) - Dormant Projects 79
Anaplastic Large Cell Lymphoma (ALCL) - Product Development Milestones 80
Featured News & Press Releases 80
Dec 07, 2014: Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting 80
Dec 06, 2014: Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting 81
Nov 07, 2014: Seattle Genetics to Present Clinical Data from Broad ADCETRIS (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugates at ASH 2014 83
Nov 06, 2014: Takeda Announces Abstracts for ADCETRIS (brentuximab vedotin) in Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma to be Presented at 56th American Society of Hematology Annual Meeting 85
Sep 24, 2014: Seattle Genetics Highlights Updated Progression-Free Survival and Overall Survival Data from ADCETRIS (Brentuximab Vedotin) Frontline PTCL Phase 1 Clinical Trial at the ESMO 2014 Congress 86
Apr 17, 2014: ADCETRIS 50mg for intravenous drip infusion", Treatment for Patients with CD30 Positive Relapsed or Refractory Hodgkin Lymphoma or Relapsed or Refractory Anaplastic Large Cell Lymphoma Now Available in Japan 88
Jan 17, 2014: Seattle Genetics Announces ADCETRIS Approval in Japan for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma 88
Jun 21, 2013: Seattle Genetics Highlights Adcetris Clinical Data At International Conference On Malignant Lymphoma 89
Jun 19, 2013: Takeda And Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival With Adcetris At International Conference On Malignant Lymphoma 91
Jun 01, 2013: Takeda Highlights Data From Phase I/II Clinical Trial Examining Use Of Adcetris in Pediatric Patients With Hodgkin Lymphoma Or Systemic Anaplastic Large Cell Lymphoma 93
Appendix 95
Methodology 95
Coverage 95
Secondary Research 95
Primary Research 95
Expert Panel Validation 95
Contact Us 96
Disclaimer 96

List of Tables
Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL), H2 2014 9
Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL) - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 11
Number of Products under Investigation by Universities/Institutes, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Products under Investigation by Universities/Institutes, H2 2014 17
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Akron Molecules AG, H2 2014 18
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by AstraZeneca PLC, H2 2014 19
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Bayer AG, H2 2014 20
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Celon Pharma Sp. z o.o., H2 2014 21
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Novartis AG, H2 2014 22
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Pfizer Inc., H2 2014 23
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Sareum Holdings plc, H2 2014 24
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Seattle Genetics, Inc., H2 2014 25
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Sigma-Tau S.p.A., H2 2014 26
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 27
Assessment by Monotherapy Products, H2 2014 28
Number of Products by Stage and Target, H2 2014 30
Number of Products by Stage and Mechanism of Action, H2 2014 32
Number of Products by Stage and Route of Administration, H2 2014 34
Number of Products by Stage and Molecule Type, H2 2014 36
Anaplastic Large Cell Lymphoma (ALCL) Therapeutics - Recent Pipeline Updates, H2 2014 62
Anaplastic Large Cell Lymphoma (ALCL) - Dormant Projects, H2 2014 79